Emerald Health Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Emerald Health Therapeutics Inc (EMHTF) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Emerald Health Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 17M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-11.6% annualized vs trailing 12 months).
- Peer revenue share: Emerald Health Therapeutics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
EMHTF Sales vs. its Competitors, Q4 2019
Emerald Health Therapeutics Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 328.4% for Emerald Health Therapeutics Inc. Emerald Health Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Emerald Health Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Emerald Health Therapeutics Inc. | - | Yes | Yes | Yes |
| High-Confidence Competitors (24) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EMHTF Stock Performance relative to its Competitors
EMHTF Stock Performance relative to High-Confidence Competitors
Emerald Health Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Emerald Health Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Artelo Biosciences Inc | Company report | 85% |
| Viking Therapeutics | Company report | 85% |
| Amgen | Company report | 85% |
| Terns Pharmaceuticals | Company report | 85% |
| Alcon | Company report | 85% |
| Biohaven | Company report | 85% |
| Omega Therapeutics | Company report | 85% |
| Zealand Pharma | Company report | 85% |
| AstraZeneca | Company report | 85% |
| Novartis | Company report | 85% |
| Altimmune | Company report | 85% |
| Keros Therapeutics | Company report | 85% |
| Pfizer | Company report | 85% |
| Structure Therapeutics | Company report | 85% |
| Abbvie | Company report | 85% |
| Inversago | Company report | 85% |
| Novo Nordisk | Company report | 85% |
| Roche | Company report | 85% |
| Carmot Therapeutics | Company report | 85% |
| Merck | Company report | 85% |
| Regeneron | Company report | 85% |
| Kallyope | Company report | 85% |
| Scholar Rock | Company report | 85% |
| Eli Lilly | Company report | 85% |
| Rivus | Company report | 85% |
| Versanis | Company report | 85% |
| Boehringer Ingelheim | Company report | 85% |
| Bausch + Lomb | Company report | 85% |
| Inmed Pharmaceuticals Inc | Company report | 85% |
| Cnbx Pharmaceuticals Inc | Company report | 85% |
| Lexaria Bioscience Corp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Emerald Health Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.